About: Glial cell type-specific changes in spinal dipeptidyl peptidase 4 expression and effects of its inhibitors in inflammatory and neuropatic pain

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Glial cell type-specific changes in spinal dipeptidyl peptidase 4 expression and effects of its inhibitors in inflammatory and neuropatic pain Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Glial cell type-specific changes in spinal dipeptidyl peptidase 4 expression and effects of its inhibitors in inflammatory and neuropatic pain
Creator	Alpár, Alán Balázsa, Tamás Barta, Benjamin Bölcskei, Kata Fekete, Csaba Gerber, Gábor Helyes, Zsuzsanna Király, Kornél Kozsurek, Márk Lukácsi, Erika Pap, Károly Puskár, Zita Szabon, Judit Tékus, Valéria Tóth, Zsuzsanna
Source	Medline; PMC
abstract	Altered pain sensations such as hyperalgesia and allodynia are characteristic features of various pain states, and remain difficult to treat. We have shown previously that spinal application of dipeptidyl peptidase 4 (DPP4) inhibitors induces strong antihyperalgesic effect during inflammatory pain. In this study we observed low level of DPP4 mRNA in the rat spinal dorsal horn in physiological conditions, which did not change significantly either in carrageenan-induced inflammatory or partial nerve ligation-generated neuropathic states. In naïve animals, microglia and astrocytes expressed DPP4 protein with one and two orders of magnitude higher than neurons, respectively. DPP4 significantly increased in astrocytes during inflammation and in microglia in neuropathy. Intrathecal application of two DPP4 inhibitors tripeptide isoleucin-prolin-isoleucin (IPI) and the antidiabetic drug vildagliptin resulted in robust opioid-dependent antihyperalgesic effect during inflammation, and milder but significant opioid-independent antihyperalgesic action in the neuropathic model. The opioid-mediated antihyperalgesic effect of IPI was exclusively related to mu-opioid receptors, while vildagliptin affected mainly delta-receptor activity, although mu- and kappa-receptors were also involved. None of the inhibitors influenced allodynia. Our results suggest pathology and glia-type specific changes of DPP4 activity in the spinal cord, which contribute to the development and maintenance of hyperalgesia and interact with endogenous opioid systems.
has issue date	2018-02-22(xsd:dateTime)
bibo:doi	10.1038/s41598-018-21799-8
bibo:pmid	29472575
has license	cc-by
sha1sum (hex)	88d9d333b7b85d34405f27fc2e469cad48a1f8c4
schema:url	https://doi.org/10.1038/s41598-018-21799-8
resource representing a document's title	Glial cell type-specific changes in spinal dipeptidyl peptidase 4 expression and effects of its inhibitors in inflammatory and neuropatic pain
has PubMed Central identifier	PMC5823904
has PubMed identifier	29472575
schema:publication	Sci Rep
resource representing a document's body	covid:88d9d333b7b85d34405f27fc2e469cad48a1f8c4#body_text
is schema:about of	named entity 'DIPEPTIDYL PEPTIDASE 4' named entity 'antidiabetic drug' named entity 'change' named entity 'strong' named entity 'neuropathic' named entity 'DPP4' named entity 'neuropathic' named entity 'activity' named entity 'inflammatory' named entity 'CELL TYPE' named entity 'ITS' named entity 'GLIAL CELL' covid:arg/88d9d333b7b85d34405f27fc2e469cad48a1f8c4 named entity 'INHIBITORS' named entity 'OPIOID' named entity 'APPLICATION' named entity 'BUT' named entity 'EXPRESSED' named entity 'INDEPENDENT' named entity 'MRNA' named entity 'RECEPTORS' named entity 'INTRATHECAL' named entity 'STUDY' named entity 'ASTROCYTES' named entity 'RELATED' named entity 'DIFFICULT' named entity 'DIPEPTIDYL PEPTIDASE 4' named entity 'INFLAMMATORY PAIN' named entity 'STATES' named entity 'SYSTEMS' named entity 'RESULTS' named entity 'VARIOUS' named entity 'PAIN SENSATIONS' named entity 'MAINTENANCE' named entity 'MAGNITUDE' named entity 'PATHOLOGY' named entity 'ALLODYNIA' named entity 'CARRAGEENAN' named entity 'ANTIDIABETIC DRUG' named entity 'IPI' named entity 'LOW LEVEL' named entity 'GENERATED' named entity 'INFLAMMATION' named entity 'ROBUST' named entity 'RAT' named entity 'ANIMALS' named entity 'GLIA' named entity 'NEUROPATHY' named entity 'SUGGEST' named entity 'KAPPA' named entity 'TREAT' named entity 'RECEPTOR ACTIVITY' named entity 'FEATURES' named entity 'CHARACTERISTIC' named entity 'OPEN' named entity 'DPP4' named entity 'EITHER' named entity 'TRIPEPTIDE' named entity 'TYPE' named entity 'DEPENDENT' named entity 'ENDOGENOUS OPIOID' named entity 'OBSERVED' named entity 'DORSAL HORN' named entity 'MEDIATED' named entity 'PARTIAL' named entity 'AFFECTED' named entity 'PREVIOUSLY'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software